Top Markets
#1 CyberDEX CyberDEX +372.54%
#2 OVERTAKE OVERTAKE +56.57%
#3 ALEO ALEO +43.43%
#4 Nillion Nillion +34.21%
#5 Clearpool Clearpool +27.85%
#6 Playnance Playnance +23.56%
#7 deBridge deBridge +23.20%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.17%
#9 AUKI AUKI +18.69%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.88%
Coin of the day
CyberDEX CyberDEX
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Rang in aandelen #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Aandeelprijs
$0.05897422
Laatst gesynchroniseerd: 2024-04-02
Marktkapitalisatie
$1.64M
Verandering (1 dag)
0.07%
Verandering (1 jaar)
-60.68%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCI)

Categorie

Healthcare
P/S-ratio voor Intellipharmaceutics International Inc. (IPCI)
P/S-ratio op September 2026 TTM: 75.52
Volgens de meest recente financiële rapporten en aandelenkoers van Intellipharmaceutics International Inc. is de huidige P/S-ratio (TTM) 75.52. Eind 2021 had het bedrijf een P/S-ratio van 53.73.
P/S-ratiohistoriek voor Intellipharmaceutics International Inc. van 1999 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 75.52 114.31%
2022 35.24 -34.41%
2021 53.73 2,358.50%
2020 2.19 -5.37%
2019 2.31 151.70%
2018 0.92 -80.84%
2017 4.79 -85.55%
2016 33.15 171.91%
2015 12.19 61.06%
2014 7.57 -85.08%
2013 50.74 -86.99%
2012 390.00 315.68%
2011 93.82 375.52%
2010 19.73 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 22.45K 2.75%
2000 21.84K 14,851.44%
1999 146.10 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 -86.17%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 -65.41%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -95.03%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 -84.10%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH